Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Shoklo Malaria Research Unit (SMRU) led Malaria Elimination Task Force has undertaken mass drug administration campaigns in Eastern Karen State, Myanmar in areas with a high sub microscopic Plasmodium falciparum parasite prevalence.

A child taking pills

Mass drug administration (MDA) is used in villages where a high percentage of people are confirmed positive for P. falciparum by ultra-sensitive qPCR. It works by eliminating this sub-microscopic reservoir of parasites and therefore probably reduces the risk of malaria transmission. In this region most of the P.falciparum isolates are resistant to artemisinins.

SMRU qPCR surveys detected 29 high prevalence hotspots in Myanmar’s Eastern Karen State, many of them hard to access. So far, 19 of these villages have undergone or are receiving mass drug administration. Only one village initially refused to participate. But thanks to community engagement efforts and the dedication and patience of our Community Engagement Team led by Ladda (Micho) Kajeechiwa, the villagers finally agreed to participate in the MDA. Overall, more than 80% of all villagers in hotspots have participated in these MDA campaigns – a very good result, as 80% is the target for effective mass drug administration.

Funded by the Wellcome Trust, The Global Fund and the Bill & Melinda Gates Foundation, the Malaria Elimination Task Force began in July 2014. This is a collaboration between SMRU and local Karen community-based organisations. The main activities include GIS mapping, community engagement, qPCR surveys to find malaria hotspots and verify that a village qualifies for mass drug administration, mosquito catching, and running malaria posts operated by villagers and using RDTs and ACTs and reporting data on a weekly basis.

Based in Mae Sot, Thailand since 1986, SMRU is a Unit of the Mahidol Oxford Tropical Medicine Research Unit (MORU), which was established in 1979 as a research collaboration between Mahidol University (Thailand), University of Oxford (UK) and the Wellcome Trust.

For more information, kindly contact John Bleho.

Similar stories

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allowed researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.